[Intravenous mogadon in epileptic patients. Clinico-electroencephalographic study].
Mogadon as a parenteral solution was employed for treating status epilepticus (15 cases), intermitent epileptic seizures (10 cases), Lennox syndrome (14 cases), myoclonic seizures (5 cases) and absences (6 cases). The dosage layed between 3,3 mg and 10 mg according to each individual case. Status epilepticus and intermitent seizures disappeared following the injection and so did the irritative EEG alterations. Remission was observed in 10 Lennox cases while the remaining 4 improved. Mogadon abolished myoclonic seizures, in some cases beyond 6 hours. In simple absence improvement was also evident, although more shortlived than in myoclonic seizures. Sleepiness was side-effect, occurring in some cases.
D004569:Electroencephalography; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D009567:Nitrazepam / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013226:Status Epilepticus / Q000188:drug therapy
D009567:Nitrazepam
Mogadon endovenoso em pacientes epilépticos. Estudo clínico-eletrencefalográfico.